BASEL, Switzerland and AARHUS, Denmark, May 8 /CNW/ - Roche, and Borean Pharma A/S, the Danish biopharmaceutical and protein engineering company, today announced that they have signed a multifaceted agreement under which Roche receives exclusive rights to develop and commercialize Trimeric Apo A-I. Apo A-I is Borean Pharma's lead candidate for the treatment of atherosclerosis, a form of heart disease. The acquisition of Borean's trimeric Apo A-I forms a strategic fit for Roche and its pipeline of anti- atherosclerotic drugs.
